Contact
Please use this form to send email to PR contact of this press release:
Inmagene Announces Positive Topline Results of a Multiple Ascending Dose (MAD) Study of IMG-004, a Non-covalent Reversible BTK Inhibitor with Once Daily Dosing Potential
TO: